Buprenorphine Prescribing: To Expand or Not to Expand

被引:23
|
作者
Li, Xiaofan [1 ]
Shorter, Daryl [1 ,2 ]
Kosten, Thomas R. [1 ,2 ]
机构
[1] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, 2002 Holcombe Blvd,Bldg 121,Off 121-137, Houston, TX 77030 USA
[2] Michael E DeBakey VA Med Ctr, Houston, TX USA
关键词
buprenorphine; prescription opioids; abuse; diversion; regulation; policy; EXTENDED-RELEASE OXYCODONE; PRESCRIPTION MONITORING PROGRAMS; OFFICE-BASED TREATMENT; PRIMARY-CARE; OPIOID ANALGESICS; TREATMENT-SEEKING; OVERDOSE DEATHS; NONMEDICAL USE; MEDICAL USE; ABUSE;
D O I
10.1097/PRA.0000000000000154
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
As a result of the prescription opioid epidemic in the United States, there has been an increasing need for effective treatment interventions, both pharmacological and nonpharmacological. Buprenorphine has emerged as a critical component of the treatment of opioid use disorder, yet its adoption has not been without some concerns. This article first reviews the pharmacology, clinical use, and US legislative action related to buprenorphine, followed by a discussion of the misuse and diversion of buprenorphine in the United States as well as internationally. We then explore the impact of buprenorphine abuse as well as discussing strategies for its reduction, including changes in policy, prescription and pharmacy monitoring, and continuing medical education for guiding and improving clinical practice.
引用
收藏
页码:183 / 192
页数:10
相关论文
共 50 条